- Home
- » Tags
- » Obinutuzumab
Top View
- Radiochemistry, Production Processes, Labeling Methods, and Immunopet Imaging Pharmaceuticals of Iodine-124
- (INN) for Biological and Biotechnological Substances
- Brentuximab Vedotin in Combination with Rituximab, Cyclophosphamide
- (CLL/SLL) TREATMENT REGIMENS (Part 1 of 3) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
- Open Full Page
- 2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
- CHMP Assessment Report
- Obinutuzumab
- PDCO Monthly Report of Opinions on Paediatric Investigation Plans and Other Activities 8-11 December 2020
- Gazyva® (Obinutuzumab)
- The Next Generation of Monoclonal Antibody
- Effect of Kinase Inhibitors on the Therapeutic Properties of Monoclonal Antibodies
- Prescribing Information
- Getting the Facts
- Bispecific Antibodies Targeting Tumor-Associated Antigens And
- Analyses of CD20 Monoclonal Antibody-Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies
- Obinutuzumab for the Treatment of Non-Hodgkin Lymphomas
- New Drug Update
- Obinutuzumab) None
- Highlights in Lymphoma from the 2019 American Society of Clinical
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Ez-Minutes February-April 2013
- Fc-Engineered Antibodies with Enhanced Fc-Effector Function For
- Oncology Medications Policy (1403)
- Gazyvaro, INN-Obinutuzumab
- Obinutuzumab As Frontline Treatment of Chronic Lymphocytic Leukemia: Updated Results of the CLL11 Study
- Emetogenic Potential of Antineoplastic Agents
- Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications
- Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory and Malignant Disease: Translating TNF-A Experience to Oncology
- Oncology Therapy for the Generalist
- (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab in Vitro and in Xenograft Models
- Pitfalls in Oncology Drug Development
- 190510 IR ASCO Curtain Raiser En Final V2
- 125486Orig1s000
- Obinutuzumab and Chlorambucil Therapy
- NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Follicular Lymphoma (Grade 1–2) (Part 1 of 3)
- Obinutuzumab and Bendamustine Therapy – 28 Day Cycle
- The Specific Bruton Tyrosine Kinase Inhibitor Acal- Mechanisms of Anti-CD20 Antibodies
- Unmet Medical Needs and Therapeutic Landscape for Recurrent Follicular and Marginal Zone Lymphoma
- Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
- A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
- Introduction to Therapeutic Antibodies
- Targeted Treatment of Follicular Lymphoma
- (Obinutuzumab), Humanized Antibody
- Newer Antibodies Against CD20 Newer Antibodies Against CD20 Are Beginning to Offer Alternatives to Rituximab for Some People with Lymphoma
- (INN) for Biological and Biotechnological Substances
- Global Oncology
- Arzerra® (Ofatumumab) and Gazyva® (Obinutuzumab)
- Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia in the Non-Hematopoietic Stem Cell Transplant Setting
- What Is New for Lymphoma and CLL Know Your Treatments EDITION 1 JANUARY 2017
- Assessment of the Evolution of Cancer Treatment Therapies
- Understanding Immunotherapy and Lymphoma
- 761121Orig1s000
- GAZYVA (Obinutuzumab) Injection, for Intravenous Use Initial U.S
- ASH 2018 Practice Changing Abstracts in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Obinutuzumab Maintenance Therapy -56 Day
- Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment
- Roche to Present Clinical Data from Six Different Medicines At
- BC CANCER CHEMOTHERAPY PREPARATION and STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative
- Arzerra® (Ofatumumab) and Gazyva® (Obinutuzumab)